NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101

Pancreatic carcinoma has a dismal prognosis at time of diagnosis, due to late onset of clinical symptoms, patients present with advance disease. Complete surgical resection is the only potential curative treatment, however only a small percentage is eligible for upfront total surgical resection due to extension into anatomical related important vascular structures. Neoadjuvant chemo(radio)therapy has become the standard treatment modality for non-primary resectable disease (borderline resectable and locally advanced pancreatic cancer (LAPC)), where subsequent downstaging can make identificatio

Trial Details

NCT ID

NCT05984810

Phase

PHASE2

Sponsor

Leiden University Medical Center

Status

RECRUITING

Cancer Type

Pancreatic Ductal Adenocarcinoma Pancreatic Cancer

Interventions

Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101

Locations (sample)

Leiden, Netherlands|52.15833,4.49306

Key Eligibility Criteria

Part A: To be eligible for inclusion in this study, patients must meet all of the following criteria:
Signed informed consent prior to any study-mandated procedure;
Patients aged over 18 years old;
Has the ability to communicate well with the Investigator in the Dutch/English language and willing to comply with the study restrictions.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →